Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 91

Comparing Treatment Efficacy, Three Purities Win Decisively

1,802 words 6 min read 8 views 4mo ago Source ​
Skip to the end of the chapter
Prev
Next

Eagle Country Biogen Company. is a leading global biopharmaceutical company treating neurological diseases Alzheimer's disease's, with annual sales tens of billions of US dollars. Last year, it ranked 20th in the Top 50 Global Prescription Drug Companies.

Aduhelm is one of Biogen's flagship drugs.

This drug can selectively bind to beta-amyloid protein in the brain, and then clear amyloid plaques from the brain by activating the immune system.

However, the road to market for this blockbuster drug was very bumpy and full of twists and turns, and it was also controversial after its launch.

When the drug was first applied for marketing approval by the FDA, it was rejected due to unclear efficacy. Biogen was about to give up on the drug, but in subsequent clinical trials, after expanding the sample and increasing the dosage, it was found that the positive effects on patients became apparent.

Biogen continued to invest in research and development, reapplied for FDA approval, and received expedited approval to launch the product.

The approval sparked considerable controversy within the industry, particularly given the strong opposition from members of the FDA advisory committee. Ten expert members resigned after the regulatory body decided to approve the drug.

The safety of Aduhelm has been a major reason for the drug's troubled history; one woman who took it died from cerebral edema. While it cannot yet be confirmed that the drug caused her death, it has significantly impacted doctors' confidence in prescribing it to patients.

Biogen continued to generate data supporting the safety and efficacy of the drug, confirming its effectiveness in treating Alzheimer's disease. At a subsequent Alzheimer's disease's Alzheimer's disease clinical trial meeting, Biogen presented data from two Phase III trials showing that, after treatment, patients experienced a reduction in amyloid plaques and a significant decrease in plasma p-tau181 (Alzheimer's disease tau marker).

The general consensus is that the FDA approved the drug because its benefits to Alzheimer's disease outweighed its risks, which primarily reflects an attitude of encouraging AD drug research.

After all, research on new drugs for treating AD) has essentially failed, with no new drugs approved in the last decade or so. This has severely dampened the research and development enthusiasm of pharmaceutical companies, and some have completely abandoned this area of research. However, with the aging of society, the development of AD treatment drugs is extremely urgent.

The FDA's accelerated approval provides patients with earlier treatment opportunities. However, the FDA has also required Biogen Company to conduct a new randomized, controlled clinical trial to further validate the clinical benefit to patients. If the subsequent trial is unsatisfactory, the FDA may withdraw its approval for the drug.

Patients and their families are eagerly awaiting this, after all, they have been waiting for far too long. The last time the FDA approved the Alzheimer's disease drug Namenda (known as "Meijingang" in China) was in 2003.

However, after the new drug was launched, its sales were dismal due to its high price and annual treatment cost of up to 60,000 US dollars. The Eagle Country. government quickly announced that it would be included in the country's medical insurance, and Biogen took the opportunity to lower the price to 30,000 US dollars annually, which finally helped to salvage the situation in the market.

However, in addition to the Eagle Country States, the drug was also rejected by drug regulators in Europa and Sakura Country at the end of last year. Both countries stated that they did not have enough data to support their approval of the drug for market.

In short, Biogen's stock price often experiences rollercoaster-like fluctuations due to news about this drug, which makes Biogen CEO very sensitive to any related news.

When he saw the news that his own drug was being compared with Three Purities's AD Special Effect Drug, he felt a sudden darkness before his eyes, and an ominous premonition instantly enveloped him.

At this moment, in a small house somewhere in the Eagle Country.

Amy Jones was intently watching the news on television, which was showing detailed clinical data analysis of Three Purities and Biogen's AD Special Effect Drug.

She had brown hair, dark eyes, a tall figure, and deep crow's feet at the corners of her eyes, making her look to be in her early forties. Her face was very calm.

As she looked at the screen, her eyes suddenly flickered with emotion. She got up, walked to the computer, and began searching online for information about this miracle drug.

As a familial Alzheimer's disease patient, with both her maternal grandmother and mother having suffered from the disease, she is very knowledgeable about it.

Globally, approximately 1%-5% of AD patients have a family history of the disease, and most develop symptoms before the age of 60, with many even starting to experience symptoms in their 40s.

This leads to greater suffering for them, because most patients do not develop the disease until after the age of 60.

Amy was already forty-two years old, and based on the experience of her mother and the other two generations, she knew that she didn't have much time left.

After years of diligently caring for her grandmother, the mother discovered she was experiencing symptoms of her illness again. Determined to end her life, she committed suicide by shooting herself rather than burden her daughter. This caused her immense emotional distress.

From then on, she lived alone in a small house in the suburbs, quietly waiting for that day to come.

Under her pillow lay the gun that had taken her mother away years ago; barring any unforeseen circumstances, this gun would also take her own life.

Before the illness completely consumed her brain, she was prepared to see her mother and grandmother at any time.

She also keeps a Bible under her pillow. Every night before going to sleep, she silently recites the book and recalls the details of her day to check if her memory is intact.

This illness was like the Sword of Damocles hanging over her head, ready to fall at any moment and claim her life.

And now, news reports are saying that a cure for this disease has been developed.

At first, she scoffed at it, after all, she had met some fellow patients through this disease, but their feedback on various drugs on the market was not very good.

This includes Biogen's special drug. One patient experienced a splitting headache after taking the drug and had to stop taking it to protect himself.

However, this Three Purities special medicine seemed a bit different, and the more she searched for related information, the more alarmed she became.

She also saw the paper in the journal Nature, and the treatment results shown therein greatly impressed her.

A longing for life slowly resurfaced in her heart.

Is there really a cure for this disease?

The paper emphasizes that this drug is only highly effective for patients in the early stages, which was sufficient for her.

She hasn't developed symptoms yet. If she keeps taking this medicine, wouldn't it delay the onset of the disease indefinitely?

Amy immediately perked up and began to pay attention to the special report on Fox News.

"The results of the Phase II clinical trial showed that the patients' conditions improved every week. Positron emission tomography (PET) imaging showed that after one month of treatment, 80% of the patients had negative PET scans, which means that the level of amyloid protein deposition in their brains was no significantly different from that of healthy people."

"At the same time, the combined indicator of patients' cognitive and daily living abilities, iADRS, showed an 89% reduction compared to the placebo group."

"The patients' amyloid plaque levels decreased by an average of 84 units, compared to a baseline of 108 (a value less than 25 indicates a negative amyloid plaque scan)."

"1% of the participants experienced mild reactions such as dizziness, nausea, palpitations, and allergies, and further clinical observation is needed."

The more she looked, the more excited she became. The data from these Phase II clinical trial all showed the powerful efficacy of the Three Purities AD Special Effect Drug, with very few side effects, which were nothing compared to the harm caused by cerebral edema.

So they immediately contacted other AD patients and shared the good news with each other.

All the patients in the Eagle Country cheered. "God, thank you for allowing the Three Purities to create such a miraculous medicine! We are finally saved!"

They are preparing to take action to get the highly effective drug Three Purities available in the Eagle Country as soon as possible.

Meanwhile, Fox News' Blanche was also facing a huge embarrassment.

The clinical data for Three Purities AD Special Effect Drug is so good that it has exceeded everyone's expectations, leaving all the authoritative experts dumbfounded. Not only does its efficacy surpass Biogen's drug, but it also far surpasses its competitors in terms of side effects.

There is finally hope for Alzheimer's disease!

This miraculous effect led to a surge in traffic, attracting even passersby who had never heard of the disease.

However, the more people saw it, the more renowned the Three Purities Special Effect Medicine became, and more and more experts were persuaded to change their tune and begin praising the medicine.

This is not the effect Blanche wanted at all. He wanted experts to criticize the drug and ruin the reputation of Three Purities.

How could this be? Three Purities didn't actually cheat; the medicine's efficacy is real?

Blanche pulled at her hair, completely baffled.

Suddenly, the phone rang. Upon closer inspection, it turned out to be Boss Mo from Fox News.

He quickly answered the phone, bracing himself for Boss Mo's wrath.

To his surprise, the voice on the other end of the phone was very satisfied with him.

"Blanche, you did a fantastic job. This news feature was excellent. We've garnered tons of traffic, and now we're the hottest media outlet on the internet."

Blanche stammered, "But boss, we said before that the Three Purities stole Pfizer's technology, which was meant to smear their reputation. Now it seems to have backfired."

"Heh, how could that be? Why would we want to smear Three Purities? It's a pharmaceutical company, and one from the Far East at that. What does its reputation have to do with us? Nothing, right? Everything we do is for traffic, for attracting attention, isn't it?"

Blanche suddenly realized. "So the process doesn't matter, the result does. As long as we get buzz and traffic, it doesn't matter what we did in between."

"Yes, you need to learn this to become a true journalist. The audience isn't important; their attention is. Do a good job and keep the topic trending. You'll benefit greatly."

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Three Purities
Eagle Country

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS